La Vecchia C, Franceschi S, Decarli A
Br J Cancer. 1984 Jul;50(1):31-4. doi: 10.1038/bjc.1984.136.
The relation between the use of combination oral contraceptives (OCs) and the risk of epithelial ovarian cancer was investigated in a case-control study conducted in Milan on 209 women below the age of 60 with histologically confirmed epithelial ovarian cancer, and 418 age-matched controls with a spectrum of acute conditions apparently unrelated to OC use. Combination oral contraceptives were used by 18 (9%) cases, and 59 (14%) controls, giving a relative risk estimate of 0.6 (95% confidence interval = 0.3-1.0, P less than 0.05). The risk of ovarian cancer decreased with increasing duration of use and the point estimate remained below unity long after cessation of use. These results were not accounted for by parity, infertility, or other identified potential confounding factors. Thus, the findings of the present study add further support to the evidence emerging from American data of a reduction of approximately 40% in the risk of epithelial ovarian cancer among women who had used oral contraceptives.
在米兰进行的一项病例对照研究中，调查了口服复方避孕药（OCs）的使用与上皮性卵巢癌风险之间的关系。该研究纳入了209名60岁以下经组织学确诊为上皮性卵巢癌的女性，以及418名年龄匹配的患有一系列明显与OCs使用无关的急性疾病的对照者。18名（9%）病例使用了口服复方避孕药，59名（14%）对照者使用了口服复方避孕药，相对风险估计值为0.6（95%置信区间=0.3 - 1.0，P<0.05）。卵巢癌风险随着使用时间的延长而降低，并且在停止使用后很长时间点估计值仍低于1。这些结果不能用生育次数、不孕或其他已确定的潜在混杂因素来解释。因此，本研究结果进一步支持了来自美国数据的证据，即使用口服避孕药的女性患上皮性卵巢癌的风险降低了约40%。
